Gastroenterology
Shortening Sofosbuvir-Velpatasvir Therapy for Non-Cirrhotic Chronic Hepatitis C: Evidence from the RESOLVE Trial in India
The RESOLVE trial demonstrates that 8 weeks of sofosbuvir-velpatasvir treatment is non-inferior to the standard 12-week regimen in treatment-naive, non-cirrhotic chronic hepatitis C patients, supporting shorter treatment duration without co
